Inovalon Holdings, Inc.

Robbins Arroyo LLP Is Investigating the Officers and Directors of Inovalon Holdings, Inc. (INOV) on Behalf of Shareholders

Robbins Arroyo LLP is investigating whether certain officers and directors of Inovalon Holdings, Inc. (NASDAQGS: INOV) violated federal securities laws by issuing materially misleading business information to the investing public. Inovalon is a technology company that provides advanced cloud-based data analytics and data-driven intervention platforms to the healthcare industry in the United States.

Inovalon Stock Declines After Disclosing News of Poor Earnings

On February 12, 2015, Inovalon held its initial public offering (“IPO”), selling 22.2 million shares and raising approximately $600 million in capital. Then, on August 5, 2015, the company announced its second quarter financial and operating results, disclosing that its earnings had been negatively affected by a higher effective income tax rate, among other factors. On this news, Inovalon stock fell $5.87 per share, or 23.1%, to close at $19.53 per share on August 6, 2015. Since the IPO, Inovalon’s stock has fallen from a first day-trading high of $33.75 per share to close at $17.39 per share on February 2, 2016, a drop of nearly 48.5%.

Inovalon Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.

 

Shareholder Information

Items marked with an asterisk (*) are required information.

First Name * Last Name *
Phone *
E-mail * Confirm: E-mail *
Number of Shares Owned:
Comments:

Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* I have read the disclaimer information
+=

    Send This Post

    Tags: